Related Experiment Videos
[Breast cancer and hormone therapy]
12nd Dept. of Surgery, Gunma University School of Medicine.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1987
Summary
Hormonal therapy for breast cancer has evolved, with tamoxifen and other agents replacing some ablative methods for advanced disease. Adjuvant therapy includes oophorectomy and tamoxifen, though results require ongoing evaluation.
Area of Science:
- Oncology
- Endocrinology
Context:
- Hormonal therapy is a key treatment for breast cancer, particularly for metastatic or recurrent cases.
- Traditional ablative therapies like oophorectomy are being re-evaluated in light of newer agents.
Purpose:
- To review recent advancements and shifts in hormonal therapy strategies for breast cancer.
- To discuss the evolving role of various hormonal agents and combined modalities.
Summary:
- The introduction of hormone receptor assays and agents like tamoxifen and high-dose medroxyprogesterone acetate has decreased the popularity of certain ablative therapies for advanced breast cancer.
- Combined modality treatments, including chemo-endocrine and multi-hormone therapies, are under investigation.
- Post-surgical adjuvant hormonal therapy commonly involves oophorectomy (surgical or irradiation) combined with long-term tamoxifen administration.
Impact:
- These evolving hormonal therapy approaches aim to improve outcomes for breast cancer patients.
- Continued research and evaluation are necessary to clarify the efficacy and optimal use of these treatments, especially concerning controversial results.